SCHEMBL6316178

SCHEMBL6316178

COc1ccc(-c2noc(N)c2C(=O)NCCC(C)C)cn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 7/20 0.47
CD274 Q9NZQ7 1/20 0.43
RAB9A P51151 2/20 0.42
LMNA P02545 1/20 0.42
CNR1 P21554 1/20 0.41
GABRA5 P31644 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.39
PIK3CD O00329 1/20 0.39
PIK3CA P42336 1/20 0.39
PIK3CB P42338 1/20 0.39
PIK3CG P48736 1/20 0.39
MKNK1 Q9BUB5 1/20 0.39
MKNK2 Q9HBH9 1/20 0.39
GAA P10253 1/20 0.39
TSHR P16473 1/20 0.39
MAPK1 P28482 1/20 0.39
NPC1 O15118 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
RECQL P46063 1/20 0.38
MTOR P42345 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6323900 0.90 GABRA1 (0.51) GABRA1CD274RAB9ALMNAGABRA5
SCHEMBL6618320 0.89 RIPK1 (0.45) GABRA1CD274RAB9ALMNAGABRA5
SCHEMBL6323447 0.88 EPHX2 (0.45) GABRA1CD274RAB9ALMNAGABRA5
SCHEMBL6315289 0.87 RAB9A (0.46) GABRA1CD274RAB9ALMNAGABRA5
SCHEMBL6620607 0.86 GABRA1 (0.47) GABRA1CD274RAB9ALMNAGABRA5
SCHEMBL6323798 0.86 GAA (0.45) GABRA1CD274RAB9ALMNAGABRA5
SCHEMBL885658 0.85 GABRA1 (0.47) GABRA1RAB9ALMNAGABRA5MKNK1
SCHEMBL6316456 0.85 GAA (0.44) GABRA1CD274RAB9ALMNAGABRA5
SCHEMBL6319295 0.85 GAA (0.44) GABRA1CD274RAB9ALMNAGABRA5
SCHEMBL6323334 0.85 GAA (0.44) GABRA1CD274RAB9ALMNAGABRA5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US claimed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP claimed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO claimed
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors PFIZER ITALIA S.R.L. (IT) 2005-03-17 US disclosed
EP-1435948-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS Pharmacia Italia S.p.A. (IT) 2004-07-14 EP disclosed
WO-2003013517-A1 AMINOISOXAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS PHARMACIA ITALIA S.P.A. (IT) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059657-A1 Aminoisoxazole derivatives active as kinase inhibitors MAP3K9, MAP3K19, MAP4K2 GABRA1 886/4885CD274 1439/4885RAB9A 1754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.